Goldman Sachs Maintains Buy on Tenet Healthcare, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jamie Perse maintains a Buy rating on Tenet Healthcare (NYSE:THC) but lowers the price target from $98 to $85.
November 09, 2023 | 4:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Tenet Healthcare but lowers the price target from $98 to $85.
The news is directly related to Tenet Healthcare. While the Buy rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100